Skip to content
IPOandMore
  • Home
  • IPO/OFS/Stocks
    • IPO Review
    • Post IPO Analysis
    • Stock Analysis
  • Buybacks / Spl Situations
    • Recent Buybacks (Last 50)
    • All BuyBacks
    • Buyback Review
    • Special Situations
  • NCDs / Fixed Income
    • Fixed Income
    • NCD ReviewNCD Analysis & Review
  • Mutual Funds
  • Personal Finance
  • NRI
  • About
  • Toggle website search
Menu Close
  • Home
  • IPO/OFS/Stocks
    • IPO Review
    • Post IPO Analysis
    • Stock Analysis
  • Buybacks / Spl Situations
    • Recent Buybacks (Last 50)
    • All BuyBacks
    • Buyback Review
    • Special Situations
  • NCDs / Fixed Income
    • Fixed Income
    • NCD Review
  • Mutual Funds
  • Personal Finance
  • NRI
  • About
  • Toggle website search

Windlas Biotech IPO

  1. Home>
  2. Windlas Biotech IPO

Windlas Biotech IPO Review

  • Post author:[email protected]
  • Post published:August 5, 2021
  • Post category:IPO Review
  • Post comments:0 Comments

Windlas Biotech IPO comprises fresh issuance of equity shares worth ₹165 crore and an offer for sale of up to 5,142,067 equity shares ( ~ Rs. 236 crore) . Windlas Biotech…

Continue ReadingWindlas Biotech IPO Review

Archives

Categories

Copyright - WordPress Theme by OceanWP